Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Cheap Valuation

<< Previous

Bullboard Posts

Next >>

Comment by gudisgoodon Jan 27, 2023 2:19am

107 Views

Post# 35249521

RE:Cheap Valuation

MrMugsy wrote: Trevor Rose’s Insights - Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable.

---------------

Cheap valuation - true.
Environment can be favorable - right.

But - don't believe that will translate into share price gain. Just not yet.

Got to have basket balls of steel for this one.

In reality, it's impossible to say when the share price reacts. But strong numbers, new deals... if these take place, the share price will eventually react, and that's what matters. Hopefully we have some attractive deals in the horizon. :)

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages